Importing and exporting biological samples: Dos and don’ts
To ensure that your drug program’s timeline stays on track, it is crucial to follow the strict guidelines for importing and exporting biological samples. Too often, there are several mistakes with execution that could have been avoided with proper planning, coordination, and communication. These errors not only lead to frustration but also can result in:
- Costly delays
- Project rework
- Logistic challenges
- Lost, delayed, or damaged samples
- Handling mishaps
Discover the 5 best practices and mistakes to avoid when navigating the import and export of biological samples.
Build a bioanalytical strategy that will ensure speed and agility
In order to build a robust bioanalytical strategy for your drug discovery program, it’s crucial to collaborate with a partner who possesses both industry expertise and a track record of operational success.
Aliri by the numbers:
- 48-hour turnarounds in discover
- 150 biological fluids & tissues
- 1 million samples analyzed
Our team of seasoned scientists, industry experts, program managers, and quality specialists can help you develop a successful bioanalytical strategy that will maximize the growth of your drug discovery investments. Work with us to gain access to a robust suite of mass spectrometry platforms, achieve quality data to quickly file your IND, NDA and CTA, and forecast potential roadblocks that may cause delays in your project’s timeline.
Download our factsheet to explore our offerings, platforms, compounds, regulations and more.
Common Approaches to Bioanalysis of Oligonucleotides
The significance of oligonucleotides (OGNTs) in drug development is increasing rapidly, as they offer promising and life-changing treatments that can improve patients’ lives. However, the promising and vast opportunities of OGNTs come with a unique set of challenges and nuances unlike other types of molecules.
Within bioanalysis, there are 5 main approaches for OGNTs to consider:
- LC/UV
- LC/MS/MS
- Hybridization LF/FD
- LC/HRMS
- Hybridization ELISA
Learn how to evaluate the pros and cons of each approach to decide what’s best for your OGNTs.
Validating the efficacy of a compound with spatial imaging
With the ever-changing drug development landscape, pharma and biotech companies have the challenging task to quickly and efficiently generate quality and unique data to file an IND. Spatial bioanalysis is a unique solution that can help you achieve this goal, while also enabling strategic and optimized decision making throughout your process.
Download this spatial bioanalysis white paper to gain insights from industry expert, Corinne Ramos, PhD. Discussion points include:
- Precision medicine development and added value
- Disease heterogeneity: Why is it? Why is it important? How do we visualize it?
Target discovery and development of composite biomarkers
Streamlining the Importing and Exporting of Biological Samples
With the evolving requirements of importing and exporting biological samples, there is a heightened priority to proactively plan, execute, and coordinate procedures. Streamlining this process can help improve logistics, ensure timely execution, and increase workflow efficiencies. Despite the complexity, importing and exporting biological samples can become a seamless and predictable phase in research and development, especially when partnering with the right bioanalytical partner.
Download this white paper to learn from industry expert Mark Vann.